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SUMMARY. With the approval of 2 direct-acting antivirals
(DAAs) in 2011 and anticipation of interferon (IFN)-free
regimens, more hepatitis C virus (HCV) chronically infected
patients are now seeking treatment. To describe the char-
acteristics of newly referred HCV patients in 2011–2012
(Era-2) and compare them to those seen in 1998–1999
(Era-1). Retrospective data were collected from HCV
patients newly referred to our tertiary liver clinics.
Advanced liver disease was defined as cirrhosis (based on
histology or Aspartate aminotransferase–platelet-ratio
index (APRI) >2), hepatic decompensation or hepatocellu-
lar carcinoma (HCC). A total of 1348 patients (538 in
Era-1, 810 in Era-2) were included. Compared to Era-1,
Era-2 patients were older (median age 56 vs 45 years),
more likely to be black (17.2% vs 11.6%) and had a longer
interval between diagnosis and referral (median 4 vs
2 years). Genotype (GT) 1 predominated in both Eras with
a significant increase in GT1a from 39.9% in Era-1 to
53.8% in Era-2. A higher per cent of patients in Era-2
were treatment experienced, but 77% had never received
treatment. Era-2 patients were more likely to have
advanced disease at referral (61.6% vs 51.5%, P < 0.001),
with an eightfold higher prevalence of HCC (21.6% vs
2.6%, P < 0.001). HCV patients newly referred in recent
years were older, predominantly infected with GT1a and
had more advanced liver disease yet only a quarter had
received HCV treatment. Reduction in HCV disease burden
will require development of treatment regimens targeted
towards patients in the current Era as well as increase in
diagnosis and referral of patients for treatment.
Keywords: hepatitis C, hepatitis C treatment, hepatocellular
carcinoma.
INTRODUCTION
Hepatitis C virus (HCV) infection is a major public health
problem. Worldwide, it is estimated that 170 million per-
sons are chronically infected with HCV [1]. The Centers for
Disease Control and Prevention estimates that 3.2 million
persons in the United States (US) are chronically infected
with HCV resulting in 10 000–12 000 deaths per year
[2–4]. Most of these people acquired HCV infection in the
1960s and 1970s, and many are now presenting with
complications of cirrhosis and hepatocellular carcinoma
(HCC) 3–5 decades after their initial infection [5].
Achievement of sustained virologic response (SVR) to
antiviral therapy is associated with improved morbidity
and mortality [6–9]. With the rapid development of direct-
acting antiviral agents (DAAs), it is anticipated that 12-
week courses of interferon-free regimens with SVR rates of
90% or higher will soon be available to most HCV patients
in whom cirrhosis has not yet developed [10–12]. Experi-
ence with interferon-free DAA regimens in patients with
cirrhosis is limited, and available data indicate that SVR
rates are lower with some regimens [12–14]. Therefore,
early diagnosis and referral for treatment are important.
It is estimated that less than 50% of persons chronically
infected with HCV in the US are aware of their infection
[15–17]. To improve the rate of diagnosis, the US Centers
for Disease Control and Prevention recently recommended a
1-time HCV testing of persons born between 1945–1965, a
birth cohort with an HCV prevalence five times higher than
those born earlier or later [18]. Numerous studies showed
that even among those who had been diagnosed, only a
small per cent of patients with chronic hepatitis C (11.6–
21%) have received and completed antiviral therapy
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[15–17,19]. Complexity of treatment regimens, frequent
and sometimes serious adverse events, lack of health insur-
ance coverage, contraindications due to medical or psycho-
social comorbidities and low SVR rates are the common
reasons cited for the low uptake of treatment [19–22].
To prepare for the launch of interferon-free regimens, we
examined the characteristics of hepatitis C patients newly
referred to our liver clinics in 2011/2012 and compared
them with patients seen in 1998/1999. We hypothesized
that compared to the 1990s, HCV patients seen in recent
years are older, have more advanced liver disease, are more
likely to be treatment experienced and are enriched for HCV
genotypes and subgenotypes that are more refractory to
treatment. If these hypotheses are confirmed, the SVR rates
of interferon-free regimens in clinical practice may be
substantially lower than those in registration trials.
METHODS
We conducted a retrospective study of consecutive adult
patients (older than 18 years) with hepatitis C, newly
referred to the liver clinics (general hepatology clinic, liver
transplant clinic and liver tumour clinic) at the University
of Michigan Health System (UMHS) in 1998/1999 (before
the approval of pegylated interferon) and 2011/2012
(around the time of approval of two protease inhibitors –
telaprevir and boceprevir). We used ICD-9 codes (070.44,
070.54, 070.70, 070.71, 155.0, 155.2, 571.5 and 571.9)
to identify patients with chronic hepatitis C. Chronic HCV
patients were defined as patients who had positive HCV
RNA test result or positive hepatitis C antibody (anti-HCV)
test result and evidence of chronic liver disease. Medical
records were reviewed using the electronic medical record
search engine (EMERSE) developed at the University of
Michigan. The study protocol was approved by our institu-
tional review board. Of a total of 1580 potentially eligible
patients, 1348 were included in the analysis and 232 were
excluded (Fig. 1).
The following data were recorded: (i) demographics,
duration from diagnosis to first clinic visit, treatment status
(treatment na€ıve vs any prior treatment with interferon-
based therapy), and clinical status (compensated vs clinical
decompensation vs HCC) at the time of presentation; (ii)
laboratory values: hepatic panel (albumin, aspartate ami-
notransferase [AST], alanine aminotransferase [ALT], total
bilirubin), platelet count, international normalized ratio
(INR) within 3 months of the first clinic visit; HCV RNA
level within 12 months of the first clinic visit and HCV
genotype at any point in time; (iii) liver imaging results
within 6 months of the first clinic visit; and (iv) liver his-
tology within 12 months of the first clinic visit (unless his-
torical biopsy showed cirrhosis).
Advanced liver disease was defined as cirrhosis (com-
pensated or decompensated without HCC) or HCC
(regardless of the presence or absence of clinical decom-
pensation or cirrhosis). HCC was diagnosed by histology
or radiology per the American Association for The Study
of Liver Diseases (AASLD) guidelines [23]. Decompensat-
ed cirrhosis was defined as history or presence of
hepatic encephalopathy, ascites or variceal bleeding. Com-
pensated cirrhosis was diagnosed based on histology
(Ishak fıbrosis score ≥5) and for the patients who did not
have a liver biopsy an AST–Platelet Ratio Index (APRI) >2
[24].
Statistical analyses
Data were recorded in an electronic database (Research
Electronic Data Capture [REDCap]) and transferred into
SPSS software version 21 (SPSS Inc., Chicago, IL, USA) for
statistical analysis. Depending on the year of presentation,
patients were grouped into two eras, Era-1 (for those first
seen in 1998 & 1999) and Era-2 (for those first seen in
2011 & 2012). Descriptive statistics, medians and inter-
quartile ranges (IQR) were calculated for continuous data,
and frequencies and percentages were calculated for cate-
gorical data. For comparisons between groups, student t-
test and Mann–Whitney tests were used for continuous
variables and chi-square test for categorical variables. A
P-value of less than 0.05 was considered statistically signif-
icant.
RESULTS
Characteristics of patients at the time of presentation
Of the 1348 patients included, 538 patients were seen in
Era-1 and 810 in Era-2. Table 1 summarizes the charac-
teristics of the patients at the time of presentation.
Demographics
Compared to Era-1, patients seen in Era-2 were older;
median age was 56 years vs 45 years (P < 0.001). Fig-
ure 2 shows a shift in age distribution of patients seen
in the two Eras with 77.3% of those seen in Era-2 vs
25.1% in Era-1 being 50 years or older at presentation
(P < 0.001). Most patients were White, but there were
more Blacks (17.2% vs 11.6%) and patients of other
races (5.2% vs 2.9%) in Era-2 than in Era-1 (P = 0.003)
(Table 1). Roughly two-thirds of the patients were men
with no difference between the two Eras.
Interval between diagnosis and presentation
Compared to Era-1, the median interval between diagnosis
and evaluation at our clinic was double in Era-2, 4 vs
2 years (P < 0.001). Only 39.5% of patients in Era-1 and
27.0% in Era-2 were seen within 1 year of diagnosis
(P < 0.001).
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HCV genotype
Hepatitis C virus (HCV) genotype data were not available
in 18.8% of patients in Era-2 and 45.5% of patients in
Era-1. Unavailability of HCV genotype result among
patients seen in Era-2 was largely confined to those seen
in the liver tumour clinic where the physicians deemed the
patients not to be HCV treatment candidates. Genotype 1
was present in 64.7% (43.7% 1a, 15.8% 1b and 5.2%
unknown subtype) of patients in Era-2 and 41.8% (21.7%
1a, 13.2% 1b and 6.9% unknown subtype) in Era-1. Geno-
types 2 and 3 were present in 5.2% and 6.3% of Era-1
patients and 7.5% and 7.0% of Era-two patients, respec-
tively (Table 1). When patients with unknown HCV geno-
type were excluded, proportions of patients with genotype
1a increased from 39.9% in Era-1 to 53.8% in Era-2, while
proportions with genotype 2 decreased from 12.6% to
6.4% and proportions with other genotypes remained
stable (Fig. 3) .
Treatment status
The per cent of patients who had received HCV treatment
prior to presentation at our clinic increased significantly
from 17.4% in Era-1 to 23.1% in Era-2 (P = 0.013), but
the vast majority of patients were treatment na€ıve.
Increase in prior treatment was observed mainly in
patients with advanced liver disease (19.1% vs 25.6%,
P = 0.043) and those who were 50 or younger (17% vs
26.4% P = 0.010).
Stage of liver disease
Liver biopsies within 12 months of presentation for non-
HCC indications were available in 293 (55.1%) patients in
Era-1 and in 189 (25.2%) patients in Era-2 (P < 0.001).
Among the patients who had liver biopsies, those in Era-2
were older, median age 55 years compared to 44 years in
Era-1 (P < 0.001). The proportions with Ishak fibrosis 3 or
4 or Ishak fibrosis 5 or 6 in both Eras were comparable;
however, a significantly lower per cent of patients in Era-2
had Ishak 0–2, 31.7% vs 41.3% (P = 0.035) (Table 1).
The proportion of patients with advanced liver disease
defined as compensated cirrhosis, decompensated cirrhosis
or HCC increased from 51.5% in Era-1 to 61.6% in Era-2
(P < 0.001). This was mainly due to an eightfold increase
in patients with HCC from 2.6% in Era-1 to 21.6% in Era-
2 (P < 0.001) (Fig. 4). Even after excluding the subset of
patients with HCC who presented to the liver tumour clinic
(74 patients), there was still a sharp increase in number of
HCC patients from 14 in Era-1 to 101 in Era-2 and an
increase in proportion of patients with advanced liver dis-
ease from 51.5% to 57.9% (P = 0.023). The proportion of
patients with decompensated cirrhosis in the two Eras was
similar, 17.7% vs 16.4%. This was true even after exclud-
ing patients specifically referred for liver transplant evalua-
tion, 9.8% vs 8.6%. The proportion of patients with
compensated cirrhosis based on a combination of histology
and APRI decreased from 31.2% in Era-1 to 23.6% in Era-
2. When APRI > 2 was used as the sole criterion for diag-
nosing compensated cirrhosis, a similar proportion of
patients in Era-1 and Era-2 met criteria for compensated
cirrhosis, 21.9% (118/538) vs 19.9% (161/810),
(P = 0.361).
Because patients in Era-2 were older, comparison of the
proportion of patients with advanced liver disease in the two
Eras was repeated after stratification for age. The proportion
of patients with advanced liver disease in the two Eras was
similar for patients <50 years old (47.9% vs 49.5%) and
those ≥50 years old (62.2% vs 65.2%), while a marked
increase in HCC from Era-1 to Era-2 was observed among
the patients who were <50 years old (2.0% vs 20.1%) as
well as those ≥50 years old (4.4% and 22.0%).
Fig. 1 Flow Diagram of Patients Evaluated in Era 1 and Era 2.
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DISCUSSION
In this study of 1348 patients with chronic hepatitis C
newly referred to our liver centre, we found as expected
patients seen in Era-2 (2011–2012) were older and more
likely to have advanced liver disease compared to those
seen a decade ago (Era-1, 1998–1999).
There were a few unexpected findings. We found that
the interval between initial diagnosis and referral to our
liver centre for patients seen in Era-2 was double that in
Table 1 Characteristics of the patients studied
1998–1999 (n = 538) 2011–2012 (n = 810) P-value*
Age
Median (IQR), Years 45 (45–50) 56 (50–60) <0.001
≥50 years 135 (25.1) 626 (77.3)
Gender
Male 349 (64.9) 512 (63.2) 0.53
Race
White 407 (85.5) 593 (77.6) 0.003
Black 55 (11.6) 131 (17.2)
Other 14 (2.9) 40 (5.2)
Duration from diagnosis
Median (IQR), Years 2 (1–4) 4 (1–12) <0.001
Treatment status
Experienced 93 (17.4) 180 (23.1) 0.013
Platelets (k/mm3) 163 (103–211) 162 (97–226) 0.34
Albumin (g/dL) 4.0 (3.5–4.2) 4.1 (3.6–4.4) 0.100
AST (U/L) 67 (42–108) 63 (39–104) 0.66
ALT (U/L) 84 (55–132) 59 (37–97) <0.001
Total bilirubin (mg/dL) 0.80 (0.6–1.1) 0.7 (0.4–1.2) 0.48
HCV RNA (Log10 IU/mL) 6.2 (5.4–8.0) 6.1 (5.5–6.6) <0.001
HCV Genotype (GT) <0.001
GT-1 225 (41.8) 524 (64.7)
GT 1a 117 (21.7) 354 (43.7) <0.001
GT 1b 71 (13.2) 128 (15.8) 0.043
Unknown subtype 37 (6.9) 42 (5.2) 0.001
GT-2 28 (5.2) 61 (7.5)
GT-3 34 (6.3) 57 (7.0)
Other 6 (1.1) 16 (2.0)
Unknown 245 (45.5) 152 (18.8)
APRI 1.2 (0.6–3.2) 1.2 (0.6–2.8) 0.2
APRI cutoffs† n = 288 n = 485
>1.5 85 (29.5%) 182 (37.5%) 0.024
>2 70 (24.3%) 146 (30.1%) 0.082
Histology
Number with biopsies‡ 293 (55.1) 189 (25.2) <0.001
Ishak fibrosis stage
Ishak 0–2 121 (41.3) 60 (31.7) 0.035
Ishak 3–4 19 (6.5) 21 (11.1) 0.072
Ishak 5–6 145 (49.5) 103 (54.5) 0.283
Unknown 8 (2.7) 5 (2.6)
Advanced liver disease 277 (51.5) 499 (61.6) <0.001
Compensated cirrhosis 168 (31.2) 191 (23.6) 0.002
Clinical Decompensation 95 (17.7) 133 (16.4) 0.553
Hepatocellular carcinoma 14 (2.6) 175 (21.6) <0.001
Results are expressed as number (%) or median (interquartile range) unless specified otherwise. †Excluding patients with
biopsy showing cirrhosis, clinical decompensation or HCC. ‡Excluding patients with HCC on biopsy. *P-value: comparison
between patients seen in 1998–1999 and 2011–2012.
© 2014 John Wiley & Sons Ltd
484 N. Talaat et al.
Era-1. Increased familiarity of primary care physicians and
gastroenterologists with hepatitis C and its treatment dur-
ing the past decade may have prompted these physicians
to evaluate and/or treat patients with hepatitis C in their
clinics and only refer those with more advanced liver
disease who had failed to respond or were unable to toler-
ate available therapies. Approved treatment for hepatitis C
in 1998–1999 consisted of standard interferon and ribavi-
rin with SVR rates of 16–28% and 66–69% for patients
with genotype 1 and 2/3 infection, respectively [25]. Pegy-
lated interferon was approved for treatment of hepatitis C
in 2001 and two protease inhibitors – telaprevir and boce-
previr – were approved for genotype 1 infection in 2011.
Triple therapy with either telaprevir or boceprevir with
pegylated interferon and ribavirin improved SVR rates to
68%-75% for treatment na€ıve patients with genotype 1
HCV [26,27]. We found that patients referred to our liver
centre in 2011–2012 were more likely to have received
prior antiviral therapy, but most (77%) remained treat-
ment na€ıve despite a median delay of 4 years from the
time of diagnosis. Thus, delay in referral in most patients
was not due to time spent on prior treatment that failed.
Other reasons that may have contributed to the delay in
referral and treatment include the low experience level and
insufficient knowledge among health-care providers caring
for HCV patients [28–30], lack of insurance coverage [20],
presence of underlying medical or psychiatric illness that
might be a contraindication for interferon and difficulty
commuting to specialist clinics [31]. Failure of patients and
providers to recognize that hepatitis C is largely an asymp-
tomatic disease until patients develop hepatic decompensa-
tion may also have contributed to delays in referral.
Finally, it is possible that patients were ‘warehoused’ while
waiting for the approval of telaprevir and boceprevir;
Fig. 2 Age distribution for each Era.
Fig. 3 Genotype distribution for each Era.
Analysis limited to subset of patients with
known genotype. GT 1 unspecified
subtype.
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however, the number of patients seen in the first half of
2011 was not different from that seen in the second half
of 2011, 48% vs 52%. The delay in referral might have
contributed to progression of liver disease accounting for a
higher per cent of patients with advanced liver disease in
Era-2.
We observed a significant increase in uptake of treat-
ment among patients age less than 50, but not in those
50 years and older although most of the latter were only
50–59 years old. Given the ageing of the HCV patient pop-
ulation in the US with the vast majority now in the 50s
and 60s, it is concerning if physicians feel that these
patients are too old to be considered for HCV treatment.
We hope the availability of shorter courses of treatment
that are interferon-free and possibly ribavirin-free will
diminish those concerns because these older patients who
had been infected for 30 years or longer are at the greatest
risk of cirrhosis and HCC. However, the high cost of new
DAAs may prevent access of patients to interferon-free
regimens.
In accordance with our hypothesis, we found an enrich-
ment of more difficult to treat HCV genotype and subgeno-
type in Era-2. Genotype 1a was more prevalent in Era-2
compared to Era-1 (43.7% vs 21.7%, P < 0.001) when all
patients were analysed and also when the analysis was
limited to those with known genotypes: 53.8% vs 39.9%
(P < 0.001). Our finding is important because while some
DAAs have pan-genotype activity, others have lower bar-
rier to resistance with genotype 1a HCV and lower SVR
rate, and some DAA combination therapies are developed
for patients with genotype 1b infection only [32].
The most prominent finding of this study was the
marked increase in advanced liver disease from 51.5% in
Era-1 to 61.6% in Era-2. This was largely due to an eight-
fold increase in HCC in Era-2 compared to Era-1. While
this sharp increase might be due to referral bias because of
the establishment of a multidisciplinary liver tumour clinic
at our institution in 2008, a significant increase in per
cent of patients with advanced liver disease persisted even
after exclusion of patients who presented to the liver
tumour clinic. Analysis of the national database also
showed a 19-fold increase in prevalence of HCV-related
HCC between 1996 and 2006 [33,34]. Our finding that
the marked increase in proportion of patients with HCC
was observed not only among those older than 50 but also
in younger patients is concerning. It is not clear whether
these patients have more rapidly progressive liver disease,
greater exposure to carcinogens or longer duration of
infection. Given that obesity and diabetes are independent
risk factors for HCC, it is possible that the growing obesity
epidemic may also play a role in the recent increase in
HCC.
There were limitations to this study. First, this is a retro-
spective chart review study and therefore it was not possi-
ble to determine the reasons behind the low uptake of HCV
treatment and the delay in referral. Second, while our goal
was to include all new hepatitis C patients seen during the
study period, a small per cent (15%) were excluded
because of the unavailability of laboratory data within the
specified window. Third, the establishment of a new multi-
disciplinary HCC clinic during the interval between the
two Eras might have increased referrals of patients with
HCC thus inflating the increase in number of patients with
HCC in the recent era, but only 42% of the HCC patients
seen in Era-2 were directly referred to the liver tumour
clinic, and a fivefold increase in HCC was still observed
after exclusion of those seen in the liver tumour clinic.
Fourth, a higher proportion with known genotype data in
Era-2 might have contributed to the increase in genotype
1a in recent era, but an increase in genotype 1a in Era-2
persisted when the analysis was limited to the subset with
known genotype data. Fifth, due to the lack of liver
Fig. 4 Prevalence of advanced liver disease for each Era. *Combination of compensated cirrhosis, clinical decompensation
and hepatocellular carcinoma (HCC).
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biopsies in many patients, we had to rely on a combination
of histology and APRI to determine which patients have
compensated cirrhosis and the decrease in performance of
liver biopsy in Era-2 might have resulted in underestima-
tion of the number of patients with compensated cirrhosis.
While APRI has been shown to be specific for detection of
cirrhosis its sensitivity is only 17–76% [35]. Unfortunately,
elastography was not available at our centre. Finally,
observations in a tertiary liver clinic may not apply to
HCV patients in the community.
In summary, our study showed that HCV patients newly
referred to a tertiary liver centre in the U.S. in 2011 and
2012 were older, had a longer duration between diagnosis
and referral to liver clinics, were more likely to be infected
with genotype 1a HCV and more likely to have advanced
liver disease, in particular HCC, compared to those seen a
decade ago. Despite being diagnosed for a longer period of
time and having access to care, three-quarters of the HCV
patients seen in 2011–2012 had not received any treat-
ment. Reduction in HCV disease burden will require devel-
opment of treatment regimens targeted towards patients in
the current Era (>50 years, predominantly genotype 1a
and advanced liver disease), improvement in early diagno-
sis and referral of infected patients to appropriate centres
for treatment, and reduction in costs of newly approved
DAAs, otherwise implementation of screening programs
and availability of highly efficacious treatment regimens
will have little impact on disease burden.
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